HomeSectors Biotechnology

Biotechnology

ResMed Q4 Results: Sales Climb 9%, Margins Slip

CSL Horizon 2 Clinical Trials Aim to Stretch Plasma

CSL Share Price Forecast 2026: UBS Sees Strong Upside for ASX Biotech Leader

Mesoblast CEO Investment Lifts His Stake to 80.8m Shares

CSL Share Price Future: Is This Australia’s Next Long-Term Winner?

Telix Pharmaceuticals PROSTACT Phase 3 Positions for Global Impact

CSL Limited’s EU Setback and What It Means for CSL Healthcare Growth Australia

CSL Share Price Prediction 2026: Strong Buy?

What Do TPG Telecom’s 2026 AGM Changes Mean for Investors?

Ramsay Santé reports strong revenue and EBITDA growth driven by healthcare operations and improved financial performance.

Ramsay Santé Results Show Strong Revenue And EBITDA Growth

COLITCO LLP accepts no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. COLITCO LLP or an associate may receive a commission for funds raised.

↑

Biotechnology

ResMed Q4 Results: Sales Climb 9%, Margins Slip

CSL Share Price Forecast 2026: UBS Sees Strong Upside for ASX Biotech Leader

Mesoblast CEO Investment Lifts His Stake to 80.8m Shares

Recent Posts

Categories

Disclaimer

Categories

Trending Posts